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Abstract 
Background 
In Cystic Fibrosis (CF), cross–sectional studies have reported sputum matrix 
metalloproteinase (MMP)-9 to be elevated and negatively correlated with FEVR1R. This 
longitudinal study examined the association between  MMP-9 and tissue inhibitors of 
metalloproteinases (TIMP) to prognostic parameters in CF.  
 
Method 
A cross-sectional survey of CF and control subjects, CF patients were followed-up for a 
median of 49months. MMP-9 and TIMP-1&2 were quantified in sputum and plasma.  
 
Results 
Seventy-three patients with CF, median age 22 years and 40 controls were recruited. Fifty-
three of these CF patients were followed up. Prospectively, in CF subjects, plasma MMP-9 
activity was adversely associated with FEVR1R (β -1.15 (95% CI -2.10, -0.20), p=0.019 and rate 
of FEVR1 Rdecline, plasma TIMP-1 was adversely associated with mortality: hazard ratio 3.66 
(1.91-7.04), p<0.001.  
Conclusions 
These associations further justify investigation of MMP-9 and TIMP-1 as biomarkers for 
short- to medium-term FEVR1 Rdecline and mortality in patients with CF. 
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Introduction 
In cystic fibrosis (CF) the major causes of morbidity and mortality are the pulmonary 
manifestations of progressive airflow obstruction and bronchiectasis. Neutrophilic release of 
proteolytic enzymes is believed to be central to the pathogenesis of CF airway damage and 
remodelling [1]. The identification of the mediators contributing to the pathophysiological 
processes of CF airway disease could provide biomarkers with the potential to predict clinical 
prognosis, and assess response to therapy. Several studies have highlighted human neutrophil 
elastase in the pathophysiology of CF airway disease and increasing evidence suggests a role 
for matrix metalloproteinases (MMP) [2,3,4].  
 
MMPs are zinc dependent enzymes implicated in extracellular matrix turnover, tissue 
degradation and repair [5]. MMP-9 is constitutively expressed by neutrophils, but 
inflammatory stimuli can induce MMP-9 expression by other airway cells [6,7,8]. MMPs are 
secreted in an inactive pro-form, activated extracellularly and inactivated by specific tissue 
inhibitors of metalloproteinases (TIMP) released by cells that often co-secrete MMPs [6]. 
MMP-9 can degrade extracellular matrix, and interacts with other substrates, including pro-
IL-8 pro-TNF-α, and pro-IL-1β. MMPs have been implicated in the pathophysiology of 
asthma and COPD [6].  
 
Several small single-centre studies have investigated MMP-9 in CF [4]. In children with 
mild/moderate lung impairment MMP-9 has been shown to be elevated in sputum and 
bronchoalveolar lavage fluid (BALF) [1,9,10]. In adults with CF, sputum and serum MMP-9 
is elevated when compared with controls and increases further during infective exacerbations 
[11,12]. Two paediatric studies have reported associations between BALF MMP-9 and FEVR1R 
[1,9].  
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 To test the hypothesis that sputum and plasma MMP-9 levels are associated with recognised 
clinical indicators of prognosis in CF, we conducted a study of children and adults with CF. 
MMP-9, TIMP-1 & 2 were measured and related to clinical parameters. A follow-up study 
was subsequently conducted to collect longitudinal clinical data and we present here the 
results of both studies. 
 
Methods 
Subjects 
A cross-sectional study of patients aged ≥8 years attending paediatric and adult CF clinics in 
Aberdeen (Royal Aberdeen Children’s Hospital, Aberdeen Royal Infirmary) and Dundee 
(Ninewells Hospital), Scotland was conducted in 2008. As in previous studies of MMP-9, all 
CF participants were symptomatically and spirometrically clinically stable, free of acute 
respiratory infections for ≥4 weeks [9,13,14]. Participants unable to spontaneously 
expectorate had sputum induced using 3.0% saline [15]. Blood samples were collected. The 
clinical data collected for CF participants included: age, sex,  height, weight, and FEVR1R. Also 
recorded were the bacterial species persistent in the sputum [16].   As described in detail 
elsewhere [17] healthy control subjects were recruited from the local population as part of 
contemporaneous studies of sputum MMP-9 in asthma and COPD. Healthy controls were 
non-smokers; without respiratory symptoms/disease or recent chest infection; had normal 
spirometry and no recent environmental tobacco smoke exposure.  Longitudinal data 
subsequent to the cross-sectional study were collected in 2012 by accessing clinical annual 
review data. The number of infective exacerbations in the year after the initial study was 
recorded, along with annual body mass index (BMI)  and FEVR1R measurements. For deceased 
patients, survival was noted.  
5 
MMP-9 in CF 
 The cross-sectional and follow-up studies were approved by Tayside Committee on Medical 
Research Ethics and the North of Scotland Research Ethics Service, respectively. All adults 
gave written informed consent and for children, parental written informed consent and the 
child’s assent was obtained.  
 
Samples, MMP-9, TIMP quantification 
The methods used to process samples, the immunoassays, assay ranges and intra and inter 
assay precision are described in detail in the supplemental materials. Quantification of 
sputum and plasma MMP-9 and TIMP and sputum supernatant protein was performed at 
TMRC Core Laboratory, University of Dundee, UK.  
 
Statistical considerations 
MMP-9 and TIMP values above and below the assay range were recorded as 1 unit above the 
upper quantification limit and as half the lower quantification limit, respectively. Plasma 
MMP-9 activity and TIMP-1 values were all within their assay range. Sputum and plasma 
MMP-9 was expressed per millilitre supernatant/plasma, as absolute values and as ratios to 
TIMP-1, TIMP-2 and sputum protein. Visual inspection of MMP and TIMP data (confirmed 
by Lillifors corrected Kolmogorov-Smirnov test) indicated that they approximated to log-
normal distributions and the data were logarithmically transformed. FEVR1R data were 
converted to standard deviation (z) scores, adjusting for age, height and sex [18]. BMI data 
were analysed as absolute values and for children as z scores [18]. Characteristics of controls 
and CF patients (similarly CF followed-up versus CF not followed-up) were compared using 
chi-squared tests, t-tests or Mann-Whitney as appropriate. Sputum and plasma MMP-9 and 
TIMP values were related to clinical parameters using t-tests and partial correlation (adjusting 
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for CF centre). Linear mixed effects models were used with random slopes and intercepts to 
model longitudinal FEVR1R and BMI data [19]. This modelling enabled MMP-9 and TIMP to 
be related to FEVR1R and BMI and rate of decline of these outcomes (interaction terms with 
age). Survival data were related to MMP-9 and TIMP values dichotomised above/below the 
median value using Kaplan-Meier plots and logrank tests. Proportional hazards models were 
used to relate survival to log-transformed MMP-9, TIMP values. Analyses were performed 
using IBM SPSS v21.0 (Armonk, NY) and SAS v9.3 (SAS Institute Inc., Cary, USA). The 
pre-study considerations of statistical power and sample size are provided in the supplemental 
material.   
 
Results 
84 adults and 73 children were attending the two CF clinics at the time of the study, with 104 
fulfilling the study inclusion criteria (patients were mainly excluded because aged <8 years, 
no CF lung disease, or post lung transplantation). 73 CF patients (53 adults, 20 children) 
volunteered to participate in the cross-sectional study. 70 (96%) provided blood samples, 59 
(81%) provided sputum samples (85% adults, 70% children), four after sputum induction. 
Forty healthy control subjects were recruited as part of contemporaneous studies of sputum 
MMP-9 in asthma and COPD [17]. Table 1 details the control and CF subjects.  For the 
follow-on study, longitudinal data were available for 53 (72.6%) of the patients with CF who 
had participated in the cross-sectional study; 15 had died, 38 provided further consent, 
median follow-up was 49 months (IQR 37-54). When compared with CF subjects not 
followed up, CF subjects in the follow-on study were older, had a greater BMI, lower FEVR1 
Rand higher sputum MMP-9 protein (MMP-9p), and higher plasma MMP-9p and TIMP-1 
(Table 1).   
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Sputum MMP-9 in CF and controls  
Compared with controls, CF subjects had significantly higher mean concentrations of sputum 
MMP-9p and MMP-9 activity (MMP-9a) and mean ratios of MMP-9 to TIMP-1, TIMP-2 and 
sputum protein, (Figure 1).  
 
Correlations between sputum and plasma MMP-9 in CF 
The geometric mean (95% CI) ratio of MMP-9a to MMP-9p in sputum was 0.33 (0.27-0.41) 
and in plasma 0.21 (0.18-0.25). Sputum MMP-9p and MMP-9a were correlated with plasma 
MMP-9a, (partial correlation coefficient 0.33, p=0.012 and 0.39, p=0.003 respectively). 
Sputum and plasma MMP-9p were not correlated. 
 
Associations between MMP-9 and FEVR1R and BMI in CF 
UCross-sectional study: 
FEVR1 Rwas weakly/moderately negatively correlated with sputum MMP-9p (correlation 
coefficient 0.32, p=0.015) and plasma MMP-9a but not correlated with sputum MMP-9a or 
plasma MMP-9p (table 2). BMI was not correlated with sputum MMP-9 but was 
weakly/moderately negatively correlated with plasma MMP-9 protein and activity (table 2). 
The associations between plasma MMP-9a and FEVR1 Rand BMI appeared to be stronger in 
adults, being of moderate strength.  
 
 
UFollow-on study: 
FEVR1R and BMI measurements for the annual reviews in the five years subsequent to the 
initial study were available for 51 subjects (2 subjects died within a year of the cross-
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sectional study). Linear mixed-effects modelling demonstrated no significant associations 
between plasma MMP-9a and prospective BMI measurements.   
 
Linear mixed-effects modelling (Table 3) demonstrated significant negative associations 
between annual FEVR1R measurements subsequent to the initial study and plasma MMP-9a 
suggesting that high plasma MMP-9a is associated with lower FEVR1R in the years following 
MMP-9 measurement. Significant negative associations were demonstrated between 
sequential annual FEVR1R measurements and multiplicative interaction terms between age and 
plasma MMP-9a suggesting that high plasma MMP-9a is associated with a more rapid 
subsequent decline in FEVR1R. The FEVR1 Rof subjects with plasma MMP-9a in the highest tertile 
declined faster at a rate of 0.12 (0.01, 0.22, p=0.032) z score units more per year increase in 
age than subjects with plasma MMP-9a in the lowest tertile.  
 
Exacerbations 
Sputum/plasma MMP-9 or TIMP were not associated with exacerbation rate in the year after 
measurement. 
 
Bacterial infection in CF 
Persistent lung bacterial infection rates were 88% (Staphylococcus aureus (SA)), 75% 
(Pseudomonas aeruginosa (PA)) and 68% (both organisms). SA infection was associated with 
elevated MMP-9p (but not MMP-9a) in sputum and plasma (supplemental figure S1). PA 
infection was associated with increased plasma (but not sputum) MMP-9 protein and activity 
(supplemental figure S2). Two-way analysis of variance was used to relate plasma MMP-9p 
to infection with both organisms, demonstrating that plasma MMP-9p concentrations were 
independently associated with these organisms (SA  coefficient β 0.1.17, 95% CI 0.38-1.95, 
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p=0.004, PA β 1.06, 0.57-1.55, p<0.001). There was no statistical interaction between SA and 
PA infection. 
 
CF survival 
Of the 73 CF subjects participating in the cross-sectional study,  15  died during the follow-
up period. Although no MMP-9 parameters were associated with survival, higher levels of 
plasma TIMP-1 were associated with increased mortality (figure 2): Mean (95% CI) survival 
of subjects with plasma TIMP-1 greater than median (47.0 (40.0-53.9) months) was less than 
those with TIMP-1 less than the median (58.4 (56.1-60.6) months), p=0.005. Multivariate 
modelling demonstrated that after adjustment for age, sex, centre, FEVR1R, and BMI, an SD 
increase in plasma TIMP-1 was associated with a 3.66 (95% CI 1.91-7.04) fold increased 
likelihood of death in the subsequent 4-5 years, p<0.001. 
 
Discussion 
We have confirmed the previous reports that sputum MMP-9 protein and activity is elevated 
in CF and negatively correlated with FEVR1R. Novel observations are that, in the short to 
medium term, plasma MMP-9a is adversely associated with subsequent rate of FEVR1 Rdecline, 
and that plasma TIMP-1 is adversely associated with CF survival. A third novel finding is 
that plasma MMP-9p is associated with SA and PA infection in CF lung disease.  
 
Several studies have reported increased sputum/BALF MMP-9p in CF adults [12] and 
children [1,8,9], however there have been no studies of sputum MMP-9a in children [9,10]. 
One study reported serum MMP-9 protein and activity to be elevated in CF adults, but there 
are no studies of serum/plasma MMP-9 in CF children. Whilst previous studies have reported 
sputum/serum MMP-9 to be elevated in CF, few have related MMP-9 to clinical prognosis. 
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FEVR1R in children has been reported to be negatively correlated with sputum MMP-9 [9] and 
BALF MMP-9:TIMP-1 ratio [1]. However no association has been reported between FEVR1R 
and sputum or serum MMP-9 protein/activity in adults. This study confirms that FEVR1R is 
negatively correlated with sputum MMP-9p and plasma MMP-9a but for the first time also 
demonstrates that the association is present and probably stronger in CF adults, perhaps 
reflecting age related changes in the microbiological and/or immunological stimuli to airway 
inflammation. In addition, we demonstrate that elevated plasma MMP-9a is associated with 
reduced FEVR1R, and with an accelerated rate of decline of FEVR1RA similar association between 
serum MMP-9 and rate of FEVR1R decline has been reported in COPD [20].  
 
In a longitudinal study similar to ours Sagel et al related a single measurement of sputum 
biomarkers, in children with CF, to rate of lung function decline in the subsequent three years 
[13]. However, the children with CF studied by Sagel et al (mean age 11.1, mean FEVR1R 95% 
predicted, and 17% lung infection with pseudomonas) differed somewhat from the current 
study that was predominantly adults (median age 24years), with impaired lung function 
(mean FEVR1R z score -3.20) and 82% lung infection with pseudomonas. Sagel et al reported 
no association between sputum MMP-9 activity and subsequent FEVR1 Rdecline, and 
considered human neutrophil elastase (HNE) to be the most informative biomarker predicting 
subsequent FEVR1 Rdecline. Notably Sagel et al did not quantify plasma HNE or MMP-9 
activity. Although we did not quantify HNE, we similarly report no association between 
sputum MMP-9 activity and FEVR1R decline.  Sagel et al reported a logR10R increase in sputum 
HNE to be associated with a 1% increase in the rate of FEVR1, Rdecline, whereas in the current 
study a logR10R increase in plasma MMP-9 activity was associated with 5.6% increase in in the 
rate of FEVR1R decline.  
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The association we report between plasma MMP-9 activity and FEVR1R may be a consequence 
of intravascular HNE activation of pro-MMP-9 by cleavage at two sites between ValineP38P 
and AlanineP39P,and between AlanineP39P and glutamic acidP40P [14]. These sites correspond with 
appropriate molecular weight for the activated MMP-9 isoform in CF sputum [14]. Further 
work will be required to confirm that the plasma MMP-9 activity associated with FEVR1R in the 
current study originates from HNE acting in the intravascular space, rather than reflecting 
‘leakage’ from the airways or secretion from airway epithelial, endothelial or smooth muscle 
cells into the intravascular space [21,22]    
 
Only one study appears to have related MMP-9 to CF severity parameters other than FEVR1R. 
Hilliard et al [1] reported that BALF MMP-9p was not associated with lung PA infection or 
F508del homozygosity. Our demonstration that MMP-9 indices, particularly plasma MMP-
9a, are associated with recognised parameters of CF severity (FEVR1R, rate of FEVR1R decline, 
BMI, and PA/SA infection) implicate MMP-9 in the airway inflammatory processes, airway 
tissue damage and the systemic inflammatory processes of CF.  
 
The association between FEVR1 Rand MMP-9a rather than MMP-9p is biologically plausible, 
reflecting the biological activity of the activated MMP-9. MMP-9 has several actions 
pertinent to the CF bronchial inflammation and tissue damage. It degrades extra-cellular 
matrix proteins and could plausibly contribute to bronchial wall destruction especially in the 
relative absence of TIMP as evidenced by the associations between the increased ratios of 
MMP-9: TIMP-1/2 and parameters of severity. In addition to tissue destruction, MMP-9 
could also contribute to CF airway inflammation.  For example MMP-9 has been implicated 
in neutrophil migration through collagen [23], and MMP-9 is a potent activator of pro-IL-1β 
12 
MMP-9 in CF 
[24] and has been reported to increase neutrophil activity and chemotaxis by truncating IL-8 
[25].  
 
A novel finding of our study was that in patients with CF plasma TIMP-1 was adversely 
associated with survival and that this association was independent of FEVR1 Rand BMI. Similar 
adverse associations with TIMP-1 have been reported in COPD [26,27,28]. TIMPs inactivate 
MMPs in equimolar ratio [6] so it is somewhat counter-intuitive that TIMP-1 was adversely 
associated with survival given that TIMPs ‘protect’ tissues from degradation by MMPs. It is 
possible that TIMP-1 may not be exerting a ‘protective’ effect because of inactivation by 
HNE that has been shown to inactivate TIMP-1 by cleavage at a site between ValineP69 PandP 
PCysteineP70 P[14].  Whatever the mechanism underlying the association with TIMP-1, the 
association we report is clinically significant, half of the CF subjects with plasma TIMP-1 in 
the highest quartile died in the subsequent 4-5 years and an SD increase in plasma TIMP-1 
almost quadrupled mortality. Further studies are required to confirm that plasma TIMP-1 is a 
prognostic biomarker for survival and whether serial TIMP-1 measurements could be used to 
guide referral for lung transplantation (identifying patients with anticipated survival <50% in 
the next two years) and/or identify patients with a poor prognosis requiring intensification of 
treatment.  
 
The current study has a number of strengths. The subjects comprised about 70% of the local 
adult CF population and were representative of the local CF population. We were able to 
follow-up a substantial proportion of the subjects for up to five years. A further strength was 
the measurement of both MMP-9 protein and activity in sputum and plasma. Limitations of 
the current study were not being able to measure plasma MMP-9 in the control subjects and 
only measuring MMP-9 once. The sputum MMP-9 measurements in normal subjects reported 
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here were from control subjects participating in local contemporaneous studies of MMP-9 in 
asthma and COPD that did not take blood samples. Although we have not directly 
demonstrated that plasma MMP-9 is elevated in CF, the positive correlations between sputum 
MMP-9 protein/activity and plasma MMP-9a suggest that the elevated sputum MMP-9 
protein and activity levels in our CF patients are likely to be reflected by elevated plasma 
levels. MMP-9 and TIMPs were only measured once and therefore we cannot comment on 
the intra-subject variability of these measurements, however it is more likely that high intra-
subject variability will generate type II errors rather than generating a type I error. An 
additional limitation was that longitudinal clinical data were not available for all the patients 
with CF who participated in the cross-sectional study. The ethical approval for the follow-up 
study required that participants were reconsented to access clinical notes and not all patients 
reconsented. The patients with CF not participating in the follow-up study differed from those 
who did, appearing to be in better health, (less likely to die, better lung function, fewer CF 
related complications, less likely to be colonised with PA, lower plasma MMP-9 and TIMP-1 
levels). Considerations of these biases suggest that they are unlikely to have generated the 
observed longitudinal association with FEVR1R, instead these biases are likely to have reduced 
the strength of the observed association. The association between TIMP-1 and survival was 
not influenced by incomplete follow-up because survival status was available for all those 
participating in the cross-sectional study. A further limitation was that many tests of 
statistical significance were conducted and it is possible that the reported associations are a 
consequence. However given the strength and consistency of the associations between cross-
sectional and longitudinal data this seems unlikely. 
 
In summary we measured sputum/plasma MMP-9 protein/activity in CF children and adults, 
and in a cross-sectional study confirmed that sputum MMP-9 levels are elevated in CF and 
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negatively correlated with FEVR1R. Plasma MMP-9a is associated with bacterial infection, and 
negatively correlated with BMI. In a prospective 4-5 year follow-up plasma MMP-9a was 
adversely associated with FEVR1 Rdecline, and plasma TIMP-1 was adversely associated with 
mortality. The magnitude of the report associations are clinically significant and justify 
further investigation into the roles of plasma MMP-9a and TIMP-1 in CF and their potential 
utility as short to medium term prognostic biomarkers. 
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Figure and Table legends 
Table 1: Characteristics of control and CF subjects participating in the cross-sectional study 
and the CF subjects who did or did not participate in the follow up study. 
Table 2: Partial correlation coefficients (adjusted for CF centre) between plasma MMP-9 and 
FEVR1R , in all CF subjects and adult CF subjects only.  
Table 3:  Results of linear mixed effects modelling (random coefficient model) relating FEVR1R 
z score to plasma MMP-9 activity, age and plasma MMP-9 activity age interaction.  
Figure 1: Box and whisker plot of MMP-9 and TIMP concentrations in the sputum 
supernatants of CF and control subjects.  
(p<0.001 for all differences between CF and control values unless indicated). 
*ratio is to sputum protein. MMP-9p = MMP-9 protein. MMP-9a = MMP-9 activity 
Figure 2: Kaplan Meier plot of survival of subjects with CF with plasma TIMP-1 
concentrations above or below the median value. 
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  Controls 
(n=40) 
CF initial 
study 
(n=73) 
p  
valueP* 
CF 
followed up 
(n=53) 
CF not 
followed up 
(n=20) 
p  
valueP+ 
Male 45.0% 54.2% 0.37 55.8% 52.4% 0.79 
Median age (IQR) 23 (20-47) 22 (16-30) 0.067 24 (17-33) 18 (15-24) 0.030 
Mean height cm (SD) 171 (8.58) 163 (9.74) <0.001 163 (10.2) 161 (11.9) 0.54 
Mean BMI  kg/mP2P (SD) 25.1 (4.02) 20.3 (3.60) <0.001 20.9 (3.18) 18.7 (3.78) 0.013 
Mean FEVR1R z-score (SD) 0.07 (1.00) -3.91 (1.92) <0.001 -4.20 (1.80) -3.20 (2.03) 0.057 
%CF liver disease  29.2%  35.3% 14.3% 0.075 
%CF diabetes mellitus  29.2%  31.4% 23.8% 0.521 
 
Sputum infection 
      
% S aureus  88%  94.1% 81.0% 0.087 
% P aeruginosa  75%  82.4% 61.9% 0.063 
% Burkholderia   8%  9.8% 4.8% 0.482 
       
Sputum       
MMP-9 protein ng/ml    2800 
(2328-3367) 
1479 
(816-2680) 
0.001 
MMP-9 activity ng/ml    826 
(646-1058) 
670 
(468-958) 
0.089 
TIMP-1 ng/ml 
 
   72.9 
(39.8-134) 
122 
(97.8-153) 
0.33 
TIMP-2 ng/ml 
 
   88.8 
(69.2-114) 
132 
(70.2-113) 
0.87 
Plasma       
MMP-9 protein ng/ml    158 
(118-210) 
71.4 
(46.2-110) 
0.005 
MMP-9 activity ng/ml    32.8 
(26.3-41.0) 
21.9 
(13.8-34.6) 
0.19 
TIMP-1 ug/ml 
 
   98.8 
(89.6-109) 
79.2 
(70.6-88.9) 
0.001 
TIMP-2 ug/ml 
 
   148 
(134-165) 
140 
(127-155) 
0.36 
 
Table 1: Characteristics of control and CF subjects participating in the initial cross-sectional 
study and the CF subjects who did or did not participate in the follow up study. 
 
*: p value CF subjects initial study vs control subjects 
+: p value CF subjects followed up vs CF not followed up (n=20). 
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Figure 1 Box and whisker plot of MMP-9 and TIMP concentrations in the sputum 
supernatants of CF and control subjects.  
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 FEVR1 Rz score 
 
 BMI 
Plasma all 
subjects 
p 
value 
adults 
only 
p 
value 
 all 
subjects 
p 
value 
adults 
only 
p 
value 
MMP-9 protein ng/ml 0.17 0.902 -0.19 0.188  -0.27 0.027 -0.13 0.370 
MMP-9 protein:TIMP-1 
ng/ng 0.07 0.623 -0.13 0.369 
 
-0.26 0.035 -0.13 0.365 
MMP-9 protein:TIMP-2 
ng/ng -0.09 0.535 -0.24 0.088 
 
-0.24 0.044 -0.19 0.188 
          
MMP-9 activity ng/ml -0.29 0.015 -0.51 <0.001  -0.37 0.002 -0.47 0.001 
MMP-9 activity:TIMP-
1 ng/ng -0.24 0.048 -0.45 0.001 
 
-0.37 0.002 -0.46 0.001 
MMP-9 activity:TIMP-
2 ng/ng -0.39 0.001 -0.53 <0.001 
 
-0.33 0.005 -0.49 <0.001 
 
Table 2: Partial correlation coefficients (adjusted for CF centre) between plasma MMP-9 and 
FEVR1R  in all CF subjects and adult CF subjects only. 
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Model 
FEVR1R:R Rsubsequent to MMP 
measurement 
 Coefficient (95% CI)  p-value 
Age -0.70(-0.11, -0.03) 0.003 
MMP-9aP+ -1.15 (-2.10, -0.20) 0.019 
   Age -0.07 (-0.11, -0.02) 0.004 
MMP-9a:TIMP-1 -0.94 (-1.72, -0.17) 0.019 
   Age -0.06 (-0.10, -0.02) 0.006 
MMP-9a:TIMP-2 -1.30(-2.01, -0.58)  <0.001 
   Age 0.14 (-0.08, 0.35) 0.216 
MMP-9a 0.53 (-1.21, 2.27) 0.547 
Age*MMP-9a -0.063 (-0.13, 0.000) 0.050 
   Age -0.52 (-0.96, -0.08) 0.022 
MMP-9a:TIMP-1 0.51 (-0.94, 1.97) 0.485 
Age*MMP-9a:TIMP-1 -0.055 (-0.11, -0.001) 0.046 
   Age 0.38 (-0.90, 0.14) 0.145 
MMP-9a:TIMP-2 -0.31 (-1.94, 1.33) 0.710 
Age*MMP-9a:TIMP-2 -0.037 (-0.10, 0.02) 0.219 
    
Table 3: Results of linear mixed effects modelling (random coefficient model) relating FEVR1R 
z score to plasma MMP-9 activity, age and plasma MMP-9 activity age interaction. 
+MMP-9a: plasma MMP-9 activity. MMP-9 and TIMP parameters transformed to logRe 
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Figure 2: Kaplan Meier plot of survival of subjects with CF with plasma TIMP-1 
concentrations above or below the median value. 
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valueP* 
CF 
followed up 
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CF not 
followed up 
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Supplemental material: methods 
Plasma and sputum samples were processed within two hours. 
Sputum supernatant processing.  
Sputum was processed in dithiothreitol (Sputolysin) as described by Pavord et al, 1997 [1]; 
Briefly, sputum plugs were selected, removed and weighed, ensuring a minimum amount of 
saliva was associated with the plugs before incubation with 4 volumes of Sputolysin for 15 
minutes at room temperature.  Total cell numbers and viability were assessed before 
separation of the supernatant from the cell pellet. All supernatant aliquots were stored at -
80PoPC and sputum samples were assayed after a single freeze-thaw cycle. A small sample 
from the cell pellet was used to generate slides which were stained with Rapidiff (Bio 
Technology Sciences Ltd) to allow assessment of differential white cell counts. The 
remaining cell pellet was processed further for isolation of  RNA. 
 
MMP-9 Assays 
MMP-9 Elisa and MMP-9 activity kits were supplied by R&D systems (Abingdon, UK) and 
validated for use in sputum supernatant and plasma by the TMRC. Assays were performed in 
accordance with the kit inserts provided, however the activity assay was read kinetically over 
4 hours as this showed better reproducibility than an end-point read. Samples were not 
chemically activated with APMA to allow estimation of endogenous enzyme activity. Sample 
dilutions for MMP-9 ELISA were 1:40 or 1:200 for sputum supernatant and 1:40 for plasma. 
Sputum was diluted 1:50 or 1:100 for MMP-9 FRET and plasma was diluted 1:50. Intra, inter 
assay precision and detectable range of the assays are outlined in Table S1.  
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TIMP Assay 
An X-Map multiplex kit (Cat # LKT003) supplied by R&D systems (Abingdon, UK) was 
used to simultaneously determine the concentrations of TIMPs 1 and 2 on a Bioplex analyser 
as per manufacturer’s instructions.  Sputum and plasma samples were diluted 1:50. The 
BioplexP®P analyser employs a dual laser and a flow based sorting and detection platform. The 
assays are based on the sandwich immunoassay principle with pre-coated analyte specific 
antibodies bound to colour coded microparticles and  respective detection antibodies are 
biotinylated for detection with Streptavidin. One laser determines the analyte being detected 
(colour coded microparticles) and the other measures the phycoerythrin derived signal which 
is proportional to the concentration of analyte. Intra, inter assay precision and detectable 
range of the assays are outlined in Table S1.  
 
Protein assay 
Sputum supernatant protein was measured colorimetrically using the Pierce 660nm Protein 
Assay Product no. 1861426. (ThermoFisher Scientific, Cramlington, UK). 
 
Statistical considerations 
MMP-9: comparison of CF vs normal controls.  
Sputum MMP-9 concentrations in the 70 CF patients recruited to the study were compared 
with MMP-9 concentrations in 40 normal control subjects recruited and characterised in a 
parallel project. With a mean sputum MMP-9 concentration of 44 ng/ml (SD 104) in normal 
control subjects [1] the current study had 80% power to detect a minimum 80% difference in 
MMP-9 levels in the sputum of CF patients and controls at the 5% level of significance. i.e 
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normal 44ng/ml, CF 79ng/ml. It is likely that the difference will be far greater; Sagel et al [2] 
reported a mean MMP-9 level in the sputum of children with mild CF of about 4000ng/ml. 
 
MMP-9 and rate of decline of FEVR1 
The median rate of decline of FEV1 in 30 adult CF patients in Grampian in five years prior to 
the reported study was 2.6%/year (mean 3.4, SD 2.6). Based on Sagel et al [2] with a mean 
MMP-9 sputum concentration of about 4000 ng/ml (SD 1700), if 70 patients were followed 
up the study would have had 80% power (at the 5% level of significance) to detect a 30% 
difference in the MMP-9 levels (ie 4000 vs 5200 ng/ml) in the sputum of the 35 CF patients 
with rates of decline of FEV1 above the median and the 35 patients with rates of decline 
below the median rate of decline (approximately 2.7%/year). 
 
The percentage and absolute differences with 70, 60 and 50 patients with CF followed up are 
detailed in table S1.  
 
Number 
followed up 
Power α % difference detectable Absolute difference 
detectable 
70 80% 0.05 30% 4000 vs 5200 ng/ml 
60 80% 0.05 31% 4000 vs 5250 ng/ml 
50 80% 0.05 34% 4000 vs 5375 ng/ml 
 
Table S1: Pre study consideration of statistical power, percentage and absolute differences 
with 70, 60 and 50 patients with CF followed up 
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Assay with 
matrix 
Supplier Cat # Intra-assay 
imprecision 
(%) 
Inter-assay 
imprecision 
(%) 
Reportable 
Range 
MMP-9 
ELISA 
sputum 
R&D 
Systems 
DMP900 <7.5 <5.0 12.5-4000 
ng/mL 
MMP-9 
ELISA 
plasma 
R&D 
Systems 
DMP900 <4.5 <4.0 12.5-800 
ng/mL 
MMP-9 
FRET 
sputum 
R&D 
Systems 
F9M00 <10.0 <9.0 12.5-1600 
ng/mL 
MMP-9 
FRET 
plasma 
R&D 
Systems 
F9M00 <10.0 <9.0 12.5-800 
ng/mL 
TIMP-1 R&D 
Systems 
LKT003 <9.0 nd 61.6- 
452000 
pg/mL 
TIMP-2 R&D 
Systems 
LKT003 <9.0 nd 588-
1680000 
pg/mL 
 
Table S2: Details of MMP-9 and TIMP assays. 
 
 
 
 
6 
MMP-9 in CF 
  
Figure S1: Box and whisker plot of plasma MMP-9protein and MMP-9 activity in CF 
subjects with and without chronic sputum colonisation with staphylococcus aureus. (p>0.1 
unless indicated). MMP-9p = MMP-9 protein. MMP-9a = MMP-9 activity 
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Figure S2: Box and whisker plot of plasma MMP-9protein and MMP-9 activity in CF 
subjects with and without chronic sputum colonisation with pseudomonas aeruginosa. MMP-
9p = MMP-9 protein. MMP-9a = MMP-9 activity  
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